Fri, Jan 30, 2015, 5:40 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • dr_geoffrey_allan dr_geoffrey_allan Jul 1, 2013 5:08 PM Flag

    Lazard has maintained buy rating

    Can't post the link but search web and you will find

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lazard Calls Insmed's Arikace 'Still Viable' Following Competitor Concern, Continues to See Massive Upside in Shares
      12:00p ET July 1, 2013 (Benzinga)
      Insmed (NASDAQ: INSM) shares are down more than 15 percent Monday morning amid a Phase 3 trial of Arikace which met a primary endpoint, but a company slideshow which revealed competitor Novartis's (NYSE: NVS) Tobi drug showed more favorable results.

      Lazard analyst Joshua Schimmer reiterated a Buy rating on Insmed following the downside. The analyst believes Arikace is "still viable" despite the concern and market reaction Monday.

      With shares of Insmed last trading at $10.16, Schimmer's $24 price target represents potential upside of about 136 percent.

15.46-0.50(-3.13%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.